research use only

N-Acetylglucosamine

Name: N-Acetylglucosamine
Brand: Selleck Chemicals
SKU: S6257
Availability: InStock
Rating: 5 (2 reviews)

Cat.No.S6257

N-Acetylglucosamine (GlcNAc) is a monosaccharide that usually polymerizes linearly through (1,4)-β-linkages. It may be helpful for the treatment of autoimmune diseases.

Chemical Structure

Molecular Weight: 221.21

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: Purity: 100.00%

100.00

Related Targets	Dyes Antineoplastic and Immunosuppressive Antibiotics ADC Cytotoxin Selection Antibiotics for Transfected Cell PROTAC Antibiotics for Mammalian Cell Culture ADC Linker Antibiotics for Plant Cell Culture PROTAC Linker Hydrotropic Agents Antibody-Drug Conjugate E3 ligase Ligand Target Protein Ligand Molecular Glues Enzyme Substrate Drug-Linker Conjugates for ADC Chelating Agent
Related Products	BAPTA-AM Rat IgG2b isotype control-InVivo Blebbistatin Methyl-β-cyclodextrin (MβCD) AP-III-a4 (ENOblock) Carbazochrome sodium sulfonate (AC-17) Ursolic Acid Osthole 4-Methylumbelliferone (4-MU) Dioscin Ethidium bromide Pitstop 2 Sesamin Bilobalide Formononetin Hesperidin Azeliragon (TTP488) L-Mimosine Carbenoxolone Sodium Vitexin N6022 Dp44mT Chlorogenic Acid Sphingosine Chrysin Coenzyme Q10 (CoQ10) Spermine Tetrahydrochloride 2-NBDG D-Lin-MC3-DMA (MC3) Morin Hydrate

Chemical Information, Storage & Stability

Molecular Weight	221.21	Formula	C₈H₁₅NO₆	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	7512-17-6	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	GlcNAc			Smiles	CC(=O)NC1C(C(C(OC1O)CO)O)O

Solubility

In vitro
Batch:

DMSO : 44 mg/mL ( (198.9 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 44 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05402345	Not yet recruiting	NGLY1 Deficiency	Eva Morava-Kozicz\|Children''s Hospital of Philadelphia\|Seattle Children''s Hospital\|Icahn School of Medicine at Mount Sinai	May 2024	Phase 2
NCT06199531	Recruiting	NGLY1 Deficiency	Grace Science LLC	February 13 2024	Phase 1\|Phase 2
NCT04201067	Enrolling by invitation	Congenital Disorders of Glycosylation	Mayo Clinic\|National Institute of Neurological Disorders and Stroke (NINDS)	October 8 2019	--
NCT01794884	Completed	Rheumatic Heart Disease\|Coronary Heart Disease	Yuejiang Liu\|Southeast University China	January 2013	Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):